The trials measure broader categories: nausea, vomiting, and "eructation" (the clinical term for belching)
There is no evidence that doses higher than 60 mg once daily confer additional significant benefit and the higher dosage is clearly less well tolerated
The primary objective is to maximize gastric emptying delay and induce a massive caloric deficit
Observational research suggests that women with higher body mass index (BMI) may experience more frequent or severe vasomotor symptoms, though the evidence remains somewhat inconsistent and may be influenced by confounding factors
Timper K, Del Ro-Martn A, Cremer AL, Bremser S, Alber J, Giavalisco P et al
By mimicking these two hormones simultaneously, tirzepatide provides a dual-target approach to weight management